Provided by Tiger Fintech (Singapore) Pte. Ltd.

GH Research PLC

13.06
-0.3800-2.83%
Post-market: 13.060.00000.00%19:49 EDT
Volume:227.17K
Turnover:3.02M
Market Cap:810.09M
PE:-16.60
High:13.60
Open:13.48
Low:12.98
Close:13.44
Loading ...

GH Research PLC Approves Key Resolutions at Annual Meeting

TIPRANKS
·
01 Aug

GH Research plc Conducted Annual General Meeting

Reuters
·
01 Aug

GH Research plc Files Amendment to 10-K Annual Report

Reuters
·
30 Jul

GH Research (GHRS) Gets a Buy from Stifel Nicolaus

TIPRANKS
·
29 Jul

TD Cowen Keeps Their Buy Rating on GH Research (GHRS)

TIPRANKS
·
24 Jul

GH Research plc Publishes R&D Update Highlighting Progress in TRD Treatment and GH001 Developments

Reuters
·
23 Jul

H.C. Wainwright Sticks to Their Buy Rating for GH Research (GHRS)

TIPRANKS
·
14 Jul

Analysts Offer Insights on Healthcare Companies: GH Research (GHRS) and Recursion Pharmaceuticals (RXRX)

TIPRANKS
·
03 Jul

GH Research (GHRS) Gets a Buy from H.C. Wainwright

TIPRANKS
·
01 Jul

GH Research Submits Complete Response to FDA for Depression Treatment GH001; Shares Rise

MT Newswires Live
·
21 Jun

GH Research submits complete IND hold response to FDA

TIPRANKS
·
21 Jun

GH Research Is Maintained at Buy by Guggenheim

Dow Jones
·
10 May

GH Research Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
09 May

GH Research Q1 EPS $(0.19) Beats $(0.39) Estimate

Benzinga
·
08 May

H.C. Wainwright Remains a Buy on GH Research (GHRS)

TIPRANKS
·
01 May

Psychedelic: Clearmind completes clinical site initiations for AUD trial

TipRanks
·
25 Apr

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

TipRanks
·
22 Mar

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

TipRanks
·
14 Mar

Guggenheim starts GH Research at Buy, sees long-term upside potential

TipRanks
·
14 Mar

GH Research Initiated at Buy by Guggenheim

Dow Jones
·
13 Mar